HC Wainwright & Co. Maintains Buy on Xeris Biopharma Holdings, Raises Price Target to $18
HC Wainwright & Co. analyst Brandon Folkes maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and raises the price target from $10 to $18.
Share
Why It Matters
A stock expert thinks Xeris is a good buy and raised their price guess to $18. When experts believe in a company more, it can mean they see something improving.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.